Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cell-derived cardiomyocytes.

INTRODUCTION Multi-electrode array (MEA) systems and human induced pluripotent stem (iPS) cell-derived cardiomyocytes are frequently used to characterize the electrophysiological effects of drug candidates for the prediction of QT prolongation and proarrhythmic potential. However, the optimal experimental conditions for obtaining reliable experimental data, such as high-pass filter (HPF) frequency and cell plating density, remain to be determined. METHODS Extracellular field potentials (FPs) were recorded from iPS cell-derived cardiomyocyte sheets by using the MED64 and MEA2100 multi-electrode array systems. Effects of HPF frequency (0.1 or 1Hz) on FP duration (FPD) were assessed in the presence and absence of moxifloxacin, terfenadine, and aspirin. The influence of cell density on FP characteristics recorded through a 0.1-Hz HPF was examined. The relationship between FP and action potential (AP) was elucidated by simultaneous recording of FP and AP using a membrane potential dye. RESULTS Many of the FP waveforms recorded through a 1-Hz HPF were markedly deformed and appeared differentiated compared with those recorded through a 0.1-Hz HPF. The concentration-response curves for FPD in the presence of terfenadine reached a steady state at concentrations of 0.1 and 0.3μM when a 0.1-Hz HPF was used. In contrast, FPD decreased at a concentration of 0.3μM with a characteristic bell-shaped concentration-response curve when a 1-Hz HPF was used. The amplitude of the first and second peaks in the FP waveform increased with increasing cell plating density. The second peak of the FP waveform roughly coincided with AP signal at 50% repolarization, and the negative deflection at the second peak of the FP waveform in the presence of E-4031 corresponded to early afterdepolarization and triggered activity. DISCUSSION FP can be used to assess the QT prolongation and proarrhythmic potential of drug candidates; however, experimental conditions such as HPF frequency are important for obtaining reliable data.

[1]  T. Itoh,et al.  QT PRODACT: a multi-site study of in vitro action potential assays on 21 compounds in isolated guinea-pig papillary muscles. , 2005, Journal of pharmacological sciences.

[2]  Gary Gintant,et al.  Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. , 2014, American heart journal.

[3]  U. Egert,et al.  Analysis of Cardiac Myocyte Activity Dynamics with Micro-Electrode Arrays , 2006 .

[4]  James A Thomson,et al.  High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. , 2011, American journal of physiology. Heart and circulatory physiology.

[5]  M. Spira,et al.  Multi-electrode array technologies for neuroscience and cardiology. , 2013, Nature nanotechnology.

[6]  Icilio Cavero,et al.  13th Annual Meeting of the Safety Pharmacology Society: focus on novel technologies and safety pharmacology frontiers , 2014, Expert opinion on drug safety.

[7]  Jerome Pine,et al.  A History of MEA Development , 2006 .

[8]  田中 智文,et al.  In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes , 2012 .

[9]  Yasunari Kanda,et al.  Image-based evaluation of contraction-relaxation kinetics of human-induced pluripotent stem cell-derived cardiomyocytes: Correlation and complementarity with extracellular electrophysiology. , 2014, Journal of molecular and cellular cardiology.

[10]  K. Sawada,et al.  Beat-to-Beat Variability in Field Potential Duration in Human Embryonic Stem Cell-Derived Cardiomyocyte Clusters for Assessment of Arrhythmogenic Risk, and a Case Study of Its Application , 2014 .

[11]  T. Kunimatsu,et al.  Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation. , 2014, Toxicology and applied pharmacology.

[12]  Yasunari Kanda,et al.  Assessment of testing methods for drug-induced repolarization delay and arrhythmias in an iPS cell-derived cardiomyocyte sheet: multi-site validation study. , 2014, Journal of pharmacological sciences.

[13]  H. R. Lu,et al.  Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines , 2008, British journal of pharmacology.

[14]  Icilio Cavero,et al.  Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative , 2014, Expert opinion on drug safety.

[15]  U. Egert,et al.  Heart on a Chip — Extracellular Multielectrode Recordings from Cardiac Myocytes in Vitro , 2005 .

[16]  N. Ziv,et al.  Evolution of Action Potential Propagation and Repolarization in Cultured Neonatal Rat Ventricular Myocytes , 2001, Journal of cardiovascular electrophysiology.

[17]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[18]  J. Gibson,et al.  Human stem cell-derived cardiomyocytes detect drug-mediated changes in action potentials and ion currents. , 2014, Journal of pharmacological and toxicological methods.

[19]  Kenji Yasuda,et al.  On-chip in vitro cell-network pre-clinical cardiac toxicity using spatiotemporal human cardiomyocyte measurement on a chip , 2014, Scientific Reports.

[20]  Clay W Scott,et al.  Human Stem Cell-Derived Cardiomyocytes in Cellular Impedance Assays: Bringing Cardiotoxicity Screening to the Front Line , 2014, Cardiovascular Toxicology.

[21]  Karl-Heinz Boven,et al.  Micro-Electrode Arrays in Cardiac Safety Pharmacology , 2004, Drug safety.

[22]  Ferran Sanz,et al.  A Multiscale Simulation System for the Prediction of Drug-Induced Cardiotoxicity , 2011, J. Chem. Inf. Model..

[23]  A. Bruening-Wright,et al.  The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. , 2010, Journal of pharmacological and toxicological methods.

[24]  N. McMahon,et al.  Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[25]  Ulrich Egert,et al.  Cellular Physiology Cellular Physiology Cellular Physiology Cellular Physiology Cellular Physiology Estimation of Action Potential Changes from Field Potential Recordings in Multicellular Mouse Cardiac Myocyte Cultures Key Words Microelectrode Array @bullet Action Potential Upstroke @bullet Action P , 2022 .

[26]  N. Kohmura,et al.  A novel method of selecting human embryonic stem cell-derived cardiomyocyte clusters for assessment of potential to influence QT interval. , 2012, Toxicology in vitro : an international journal published in association with BIBRA.

[27]  Gary A Gintant,et al.  The Utility of hERG and Repolarization Assays in Evaluating Delayed Cardiac Repolarization: Influence of Multi-Channel Block , 2004, Journal of cardiovascular pharmacology.

[28]  Andreas Möller,et al.  On Micro-Electrode Array Revival: Its Development, Sophistication of Recording, and Stimulation , 2006 .

[29]  G. Loeb,et al.  A miniature microelectrode array to monitor the bioelectric activity of cultured cells. , 1972, Experimental cell research.

[30]  K. Sawada,et al.  Low-density plating is sufficient to induce cardiac hypertrophy and electrical remodeling in highly purified human iPS cell-derived cardiomyocytes. , 2014, Journal of pharmacological and toxicological methods.

[31]  Gary Gintant,et al.  An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation. , 2011, Pharmacology & therapeutics.